Sakineh Kazemi Noureini1, Michael Wink. 1. Department of Biology, Faculty of Basic Sciences, Tarbiat Moallem University of Sabzevar, Sabzevar, Iran. s-kazemi@sttu.ac.ir
Abstract
AIM: To investigate the potential effects of chelidonine, the main alkaloid of Chelidonium majus, on telomerase activity and its regulation in HepG2 cells. METHODS: Cytotoxicity of chelidonine for HepG2 cells was determined by neutral red assay. A modified polymerase chain reaction (PCR)-based telomerase repeat amplification protocol was used to estimate relative telomerase activity in chelidonine-treated cells in comparison with the untreated control cells. Relative expression level of the catalytic subunit of telomerase (hTERT) gene and P-glycoprotein (pgp) were estimated using semi-quantitative real-time reverse transcription-PCR (RT-PCR). Cell senescence in treated cells was demonstrated using a beta-galactosidase test. RESULTS: Cytotoxicity of chelidonine in HepG2 cells was not dose-dependent and tended to reach plateau immediately after the living cells were reduced in number to slightly higher than 50%. However, 12 micromol/L concentration of chelidonine was considered as LD(50), where the maximal attainable effects were realized. Real-time RT-PCR data showed that the expression of pgp increased three-fold in chelidonine treated HepG2 cells in comparison with the untreated controls. Morphologically, treated HepG2 cells showed apoptotic features after 24 h and a small fraction of cells appeared with single blister cell death. The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). Telomerase activity was reduced considerably after administration of very low doses of chelidonine, whereas higher concentrations of chelidonine did not remarkably enhance the effect. Real-time RT-PCR experiments indicated a drastic decrease in expression level of hTERT subunit of telomerase under treatment with chelidonine. Repeated treatment of cells with very low doses of chelidonine caused a decline in growth rate by 4 wk and many of the cells appeared to be aged with large volume and dark staining in the beta-galactosidase assay. CONCLUSION: Chelidonine reduces telomerase activity through down-regulation of hTERT expression. Senescence induction might not be directly caused by reducing telomerase activity as it occurs after a few population doublings.
AIM: To investigate the potential effects of chelidonine, the main alkaloid of Chelidonium majus, on telomerase activity and its regulation in HepG2 cells. METHODS:Cytotoxicity of chelidonine for HepG2 cells was determined by neutral red assay. A modified polymerase chain reaction (PCR)-based telomerase repeat amplification protocol was used to estimate relative telomerase activity in chelidonine-treated cells in comparison with the untreated control cells. Relative expression level of the catalytic subunit of telomerase (hTERT) gene and P-glycoprotein (pgp) were estimated using semi-quantitative real-time reverse transcription-PCR (RT-PCR). Cell senescence in treated cells was demonstrated using a beta-galactosidase test. RESULTS:Cytotoxicity of chelidonine in HepG2 cells was not dose-dependent and tended to reach plateau immediately after the living cells were reduced in number to slightly higher than 50%. However, 12 micromol/L concentration of chelidonine was considered as LD(50), where the maximal attainable effects were realized. Real-time RT-PCR data showed that the expression of pgp increased three-fold in chelidonine treated HepG2 cells in comparison with the untreated controls. Morphologically, treated HepG2 cells showed apoptotic features after 24 h and a small fraction of cells appeared with single blister cell death. The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). Telomerase activity was reduced considerably after administration of very low doses of chelidonine, whereas higher concentrations of chelidonine did not remarkably enhance the effect. Real-time RT-PCR experiments indicated a drastic decrease in expression level of hTERT subunit of telomerase under treatment with chelidonine. Repeated treatment of cells with very low doses of chelidonine caused a decline in growth rate by 4 wk and many of the cells appeared to be aged with large volume and dark staining in the beta-galactosidase assay. CONCLUSION:Chelidonine reduces telomerase activity through down-regulation of hTERT expression. Senescence induction might not be directly caused by reducing telomerase activity as it occurs after a few population doublings.
Authors: A Ludwig; G Saretzki; P S Holm; F Tiemann; M Lorenz; T Emrich; C B Harley; T von Zglinicki Journal: Cancer Res Date: 2001-04-01 Impact factor: 12.701
Authors: K Damm; U Hemmann; P Garin-Chesa; N Hauel; I Kauffmann; H Priepke; C Niestroj; C Daiber; B Enenkel; B Guilliard; I Lauritsch; E Müller; E Pascolo; G Sauter; M Pantic; U M Martens; C Wenz; J Lingner; N Kraut; W J Rettig; A Schnapp Journal: EMBO J Date: 2001-12-17 Impact factor: 11.598
Authors: Hei Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Kyu Hyun Park; Tae Soo Kim; Jin Ju Kim; Jae Kyung Roh; Hyun Cheol Chung Journal: Oncol Lett Date: 2017-06-21 Impact factor: 2.967
Authors: Koppany Visnyei; Hideyuki Onodera; Robert Damoiseaux; Kuniyasu Saigusa; Syuzanna Petrosyan; David De Vries; Denise Ferrari; Jonathan Saxe; Eduard H Panosyan; Michael Masterman-Smith; Jack Mottahedeh; Kenneth A Bradley; Jing Huang; Chiara Sabatti; Ichiro Nakano; Harley I Kornblum Journal: Mol Cancer Ther Date: 2011-08-22 Impact factor: 6.261
Authors: Anna Och; Katarzyna Szewczyk; Łukasz Pecio; Anna Stochmal; Daniel Załuski; Anna Bogucka-Kocka Journal: Oxid Med Cell Longev Date: 2017-08-30 Impact factor: 6.543
Authors: Sylwia Zielińska; Anna Jezierska-Domaradzka; Magdalena Wójciak-Kosior; Ireneusz Sowa; Adam Junka; Adam M Matkowski Journal: Front Pharmacol Date: 2018-04-11 Impact factor: 5.810